Imagen Therapeutics
- Company typePrivate
- Founded2007
- HeadquartersManchester, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
Imagen Therapeutics firmographics
Firmographics- Name
- Imagen Therapeutics
- Website
- https://imagentherapeutics.com
- Company type
- Private
- Founded year
- 2007
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Imagen Therapeutics industry classification
Industry- Product category
- Oncology Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Translational Medicine & Biomarkers (HLAIALAF)
- akta.pro secondary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Imagen Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Manchester
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Imagen Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Imagen Therapeutics product offering
Product offeringCore offering
Imagen Therapeutics is a biotech company offering personalised oncology diagnostics, contract research services, and operates a world-leading Biobank that supplies biological samples and research support to cancer research and pharmaceutical development programs. The company combines biomarker-driven diagnostic capabilities with curated patient samples to serve translational oncology needs.
Differentiator
Problem solved
Functional benefit
Products and services
- Personalised Oncology Diagnostics
Companies that use Imagen Therapeutics
Customer profileIdeal customer profiles2 records
Imagen Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Imagen Therapeutics partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights2 records
Imagen Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Foundation Medicine: Foundation Medicine, a Roche subsidiary, is a molecular information and genomics company providing comprehensive genomic profiling for oncology, offering comparable personalised oncology diagnostics as part of a broader commercial portfolio.
- Charles River Laboratories: Charles River Laboratories is a major contract research organisation offering preclinical and clinical research services and biological sample repositories, comparable to Imagen's CRO services and biobank offerings as part of a much broader scientific services portfolio.
- Bio-Techne: Bio-Techne provides reagents, assays, and diagnostic tools used in cancer and translational research, overlapping with Imagen's diagnostics and translational biomarker offerings as part of a larger life science tools and diagnostics portfolio.
- Eurofins Scientific: Eurofins Scientific is a global laboratory services group providing diagnostics, bioanalytical services, and clinical research support, comparable in offering combinations of diagnostics, contract research, and biobank-related services across multiple geographies.
Direct peers
- Natera: Natera is a personalised diagnostics company with oncology-focused molecular testing products, directly comparable to Imagen's personalised oncology diagnostics positioning and serving overlapping biopharma and clinical customer segments.
- Personalis: Personalis is a US-based personalised cancer diagnostics company providing molecular profiling and biomarker testing, closely comparable to Imagen's stated personalised oncology diagnostics offering. Both serve pharma and clinical customers with tumour-informed genomic insights.
- Myriad Genetics: Myriad Genetics develops and commercialises molecular diagnostic tests, particularly in oncology, with a focus on personalised risk assessment and treatment selection, directly comparable to Imagen's personalised oncology diagnostics offering.
- Guardant Health: Guardant Health is a leading precision oncology company specialising in liquid biopsy and blood-based cancer diagnostics, overlapping with Imagen's personalised oncology diagnostics focus and serving oncology and biopharma customers.
- NeoGenomics: NeoGenomics is a specialised oncology-focused clinical laboratory and contract research services provider, comparable to Imagen's combination of oncology diagnostics, CRO services, and biobank operations serving pharma, clinicians, and researchers.
Regional players
- Crescendo Biologics: Crescendo Biologics is a UK-based biotech developing T cell engagers and antibody-based therapeutics, comparable as a Cambridge/UK-based small private life sciences company with personalised, biomarker-driven oncology programs targeting similar translational and pharma partnership customers.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Imagen Therapeutics social profiles
Digital presenceImagen Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Imagen Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Imagen Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Imagen Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Imagen Therapeutics
What does Imagen Therapeutics do?
Imagen Therapeutics is a biotech company offering personalised oncology diagnostics, contract research services, and operates a world-leading Biobank that supplies biological samples and research support to cancer research and pharmaceutical development programs. The company combines biomarker-driven diagnostic capabilities with curated patient samples to serve translational oncology needs.
When was Imagen Therapeutics founded?
Imagen Therapeutics was founded in 2007. It employs 11 to 50 people.
Where is Imagen Therapeutics based?
Imagen Therapeutics is headquartered in Manchester, United Kingdom, in the Europe region.
Who are Imagen Therapeutics's main competitors?
Broad incumbents on record are Foundation Medicine, Charles River Laboratories, Bio-Techne and Eurofins Scientific. Direct peers are Natera, Personalis, Myriad Genetics, Guardant Health and NeoGenomics. Crescendo Biologics is listed as a regional player.
Does Imagen Therapeutics have an API?
No public API is recorded for Imagen Therapeutics.
What industry is Imagen Therapeutics in?
Imagen Therapeutics's product category is Oncology Diagnostics. Its primary akta.pro industry code is HLAIALAF, Translational Medicine & Biomarkers, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2835.